# Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

> **NCT01578967** · NA · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 41 (actual)

## Conditions studied

- Hodgkin Lymphoma, Adult

## Interventions

- **DRUG:** Brentuximab vedotin
- **DRUG:** ABVD

## Key facts

- **NCT ID:** NCT01578967
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2016-08-10
- **Final completion:** 2020-12-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578967, "Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01578967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*